Mar 17, 2022 — 5 min read
Lunit's latest study provides evidence for Lunit SCOPE IO's ability to predict immunotherapy response
This is the first study that adopted AI technology to define the tumor immune phenotype and to demonstrate its ability in predicting treatment outcomes of anti-PD-L1 therapy
SEOUL, South Korea, March 16, 2022 /PRNewswire/ -- Lunit, a leading startup in AI-based cancer solutions, announced today the publication of its study in the Journal of Clinical Oncology (JCO). Findings from the study validate the effectiveness of Lunit's AI biomarker, Lunit SCOPE IO, in predicting clinical outcomes of immunotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Lunit's AI biomarker platform, Lunit SCOPE IO
The JCO is an international, peer-reviewed medical journal published by the American Society of Clinical Oncology (ASCO), with an impact factor (IF) of 44.54. This is the first time that research on AI biomarkers has been published in an international SCI-grade journal of JCO's prestige.
"Immune phenotyping of tumor microenvironment is a logical biomarker for immunotherapy, but objective measurement of such would be extremely challenging," said Professor Tony Mok from the Chinese University of Hong Kong, co-senior author of the journal. "This is the first study that adopted AI technology to define the tumor immune phenotype, and to demonstrate its ability in predicting treatment outcomes of anti-PD-L1 therapy in two large cohorts of patients with advanced non-small cell lung cancer."
Immune checkpoint inhibitors (ICI) are a standard therapy method for advanced NSCLC with programmed death ligand-1 (PD-L1) expression. However, outcomes vary depending on the patient's tumor microenvironment.
Assessing the PD-L1 tumor proportion score (TPS) can bring predictive benefit for patients with high expression (over 50%), who show superior response to ICI therapy over standard chemotherapy. However, ICIs lose their potency in patients with PD-L1 TPS between 1% and 49%, showing outcomes similar to chemotherapy. Therefore, the development of an accuracy-enhanced biomarker to predict ICI response in NSCLC patients with low PD-L1 expression is highly warranted.
While tumor infiltrating lymphocytes (TIL) are promising biomarkers for predicting ICI treatment outcomes apart from PD-L1, clinical application remains challenging as TIL quantification involves a manual evaluation process bound to practical limitations of interobserver bias and intensive labor. Employing AI's superhuman computational capabilities should open new possibilities for the objective quantification of TIL.
To validate immune phenotyping as a complementary biomarker in NSCLC, researchers divided 518 NSCLC patients into three groups based on their tumor microenvironment: inflamed, immune-excluded, and immune-desert. As a result, clinical characteristics based on each immune phenotype group showed statistically significant differences in progression-free survival (PFS) and overall survival (OS).
Furthermore, analysis of NSCLC patients with PD-L1 TPS between 1% and 49% based on their immune phenotype found that the inflamed group showed significantly higher results in objective response rate (ORR) and progression-free survival (PFS), compared to the non-inflamed groups. This shows Lunit SCOPE IO's ability to supplement PD-L1 TPS as a biomarker by accurately predicting immunotherapy response for patients with low PD-L1 TPS.
"Lunit has demonstrated through several abstracts the credibility of Lunit SCOPE IO as a companion diagnostic tool to predict immunotherapy treatment outcomes," said Chan-Young Ock, Chief Medical Officer at Lunit. "This study is a proof-of-concept that compiles all of our past research that elucidates Lunit AI's ability to optimize cancer treatment selection."
Last year, Lunit announced a strategic investment of USD 26 million from Guardant Health, Inc., a leading precision oncology company. Following this major collaboration intended to reshape and innovate the precision oncology landscape, Lunit continues to refine its global position by validating the effectiveness of its AI technology through various studies.
Lunit wins Tumor Proliferation Assessment Challenge (TUPAC) 2016
Lunit to showcase AI-powered products at USCAP 2017
Lunit to Present Abstracts on AI-powered Precision Pathology at 2019 AACR Annual Meeting
Lunit to Present Findings on the Predictive Power of AI Biomarker for Lung Cancer Immunotherapy at ASCO 2019
Renowned Oncologist Dr. Tony Mok Joins Lunit Advisory Board
Lunit to Present Findings on the Predictive Power of AI-based Analysis of Immune Phenotype at ASCO 2020
Lunit Presents AI-powered Pathologic Classification of Immune Phenotype that Predicts Response to Immunotherapy at USCAP 2021
AACR 2021 - Lunit Presents Abstracts Demonstrating the Potential of its AI Biomarker in Cancer Treatment
AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021
Lunit Secures $26M Investment from Guardant Health in a Strategic Funding Round
Lunit AI Applied to Clinical Trial for Drug Development for the First Time--Findings Presented at ESMO 2021
Lunit to Participate in RSNA 2021, Presenting its New AI Solutions for Digital Breast Tomosynthesis and Chest CT
Lunit Expands Team with Multiple Industry Leaders to Accelerate its Business Growth
Lunit Presents Studies at SITC 2021, Highlighting the Effectiveness of AI in Predicting Response to Immunotherapy in a Clinical Trial Setting
Research Backs Clinical Efficacy of Lunit's Radiology AI Products; Abstracts to be Presented at RSNA 2021
Lunit Named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Lunit AI Demonstrates Accuracy in Practical Assessment of Cancer Tissue-Findings to Be Presented at USCAP 2022
New Studies at AACR 2022 Highlight Lunit SCOPE’s Immune Phenotyping Capabilities
Medical AI Startup Lunit gets Preliminary Approval to go Public on KOSDAQ
Lunit AI solution for PD-L1 expression analysis receives CE mark
Lunit to Present 11 Abstracts at the 2022 ASCO Annual Meeting
Lunit AI Biomarker PD-L1 Demonstrates Clinical Efficacy as Diagnostic Aid in Cancer Treatment–Published in the European Journal of Cancer
New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment